Eamonn Hobbs

Partner, Senior Client Advisor

BiotechExec

Feb 2021 - Current (5 years 9 months)

Partner and Member of the Senior Executive Advisory Team, providing commercialization and growth consulting to biotech and medtech companies.

Founder, President & CEO

Syncromune

Dec 2020 - Current (5 years 11 months)

syncromune™ is a clinical stage biopharmaceutical company focused on the development of a new generation of personalized medicine for metastatic cancers. We uniquely specialize in optimizing intratumoral immunotherapy, and endeavor to be the world leader in this new class of immunotherapy. We are advancing the development of our promising SYNC-T™ platform for several types of metastatic solid tumor cancers.

SYNC-T™ is a novel platform technology that uses intratumoral sync technology™ (IST) to synchronize the timing and location of 3 critical components within the tumor microenvironment and draining lymph nodes: liberated tumor antigens, immune system components and our proprietary multi-molecule immunotherapeutic drug.

T

Visiting Scholar and Entrepreneur in Residence

Translational Accelerator Brigham and Womens Hospital Harvard Medical School

Oct 2016 - Current (10 years 1 month)

The mission of the Translational Accelerator is to provide scientists the necessary tools, training, and resources to facilitate and accelerate the translation of inventions with potential commercial value from bench to bedside.
 Involved in the advising, training and mentoring of physician scientist inventors affiliated with the Brigham and Women’s Hospital and Harvard Medical School.
 Assist the scientists in advancing their inventions and efficiently increasing their commercial value.

M

Chairman of the Board of Directors

Marvao Medical

Jan 2014 - Current (12 years 10 months)

Marvao has developed a potentially game changing platform technology that seeks to dramatically reduce catheter infections by revolutionizing how tunneled catheters are placed and maintained. In initial clinical data comprised of thousands of catheter days, the NexSite tunneling system has demonstrated a zero catheter related blood infection rate, (CRBI) and even more remarkable, NexSite has done this in some of the most challenging applications such as femoral dialysis catheters (which normally have a very high 5-7% CRBI rate). CRBI has risen to be one of the highest profile issues with hospital administrators since it is life threatening, treatment costs are very high but not reimbursed, and reducing the hospital CRBI rate recently b

H

President

Hobbs Medical Ventures LLC

Nov 2013 - Current (13 years)

Founded by Eamonn Hobbs, Hobbs Medical Ventures is a consulting firm specializing in developing, delivering and implementing solutions for the medical device and combination medical device/pharmaceutical industries.

Mr. Hobbs is an entrepreneurial senior executive with over 30 years of demonstrated success in profitable medical device business creation, strategy, general management, sales and marketing, and product development.

He is a high-integrity, passionate leader known for exceptional abilities in developing strong customer/physician relationships and building top-performing sales and operational teams.

Areas of excellence include:
• Strategy
• Product Innovation & Development
• Succe

H

Member of the Board of Directors

Harmonic Medical Inc

Jan 2012 - Current (14 years 10 months)

Member of the Audit, Governance and Compensation Committees.
Harmonic Medical is a Toronto based development stage company involved in the development of proprietary ultrasound guided high intensity focused ultrasound (HIFU) therapy systems.

M

Prior Chairman of the Board of Directors

Medical Device Manufacturers Association

Jan 2005 - Current (21 years 10 months)

The Medical Device Manufacturers Association (MDMA) is a national trade association based in Washington, D.C. that represents independent manufacturers of medical devices, diagnostic products and health care information systems. MDMA seeks to improve the quality of patient care by influencing government policy, encouraging the development of new medical technology, and fostering the availability of beneficial innovative products.

Member, Executive, Governance, Membership and Compensation Committees

I

Chairman and CEO

ImmunSYS Inc

Jan 2018 - Sep 2020 (2 years 9 months)

ImmunSYS is an immunotherapeutic drug and device company focused on the development of a new late stage metastatic prostate cancer therapy called MyVaccx™.

MyVaccx™ empowers the patient’s own immune system to fight off cancer. It achieves this via a focal treatment of the solid tumor via a proprietary antigen presentation medical device system, immediately followed by the intra-tumoral injection of a proprietary depot drug formulation that contains a combination of immunotherapeutics and immunostimulants. The immune system then immediately creates an autologous vaccine that attacks the cancer throughout the body.

The MyVaccx™ Phase I data is compelling in that the therapy has delivered a 35% complete response rate

Executive Chairman

IlluminOss Medical Inc

Mar 2017 - Nov 2017 (9 months)

IlluminOss Medical has developed a platform, disruptive technology for the orthopedic trauma market. It has achieved CE Mark approval in Europe, and has filed for expanded indications there. IlluminOss has also completed its US pivotal clinical trial and is pursuing FDA approval via a De Novo 510(k) that is currently under review. The technology centers around image guided, minimally invasive conforming orthopedic implants that leverage it’s proprietary bone stabilization technology, the "IlluminOss System". Through the unique and proprietary combination of balloons, light activated monomers and flexible catheters, IlluminOss has created the world’s first patient conforming intramedullary implant. The IlluminOss System has been safely an

D

President & CEO

Digital Cognition Technologies Inc

Dec 2016 - Jul 2017 (8 months)

DCT was founded in 2015 with the goal of bringing to market easy to administer and non-invasive tests to detect presymptomatic cognitive impairment. Based on over 10 years of research and development at Lahey Hospital & Medical Center and MIT, our patented technology is proven to deliver accurate and objective indicators of cognitive function and is poised to make a significant impact on the medical community.
 DCT develops tests that detect presymptomatic cognitive impairment and aid in tracking cognitive change. In under 2 minutes, the technology can identify subtle cognitive features that may be indicative of impairment, even in people who appear to be functioning normally.
 All DCT’s tests are designed to be non-invasive and

Board Member

OraSure Technologies

Mar 2016 - Mar 2024 (8 years 1 month)

Member, Audit and Compensation Committees
OraSure Technologies, NASDAQ: OSUR, is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick® platform, oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health o

Interim President and CEO

Antares Pharma Inc

Jun 2014 - Jan 2016 (1 year 8 months)

Antares Pharma is a revenue-generating product focused specialty pharmaceutical company that has developed three proprietary platforms, two of which now include FDA approved products. Our products typically improve safety and efficacy profiles by minimizing dosing and reducing side effects while improving patient compliance. We focus on self-injection pharmaceutical products and technologies and topical gel -based products. Our subcutaneous injection technology platforms include Vibex™ disposable pressure-assisted auto injectors, Vision® reusable needle-free injectors, and disposable multi-use pen injectors. Antares operates in two locations with the corporate offices in Ewing, NJ, and the Parenteral Products Division in Minneapolis, MN.

Chairman of the Board

Morris Innovative

Dec 2013 - Dec 2015 (2 years 1 month)

Morris Innovative has developed and is commercializing two vascular closure device systems called FISH, which stands for Femoral Inserted Sheath Hemostasis. FISH CombiClose is a very unique combination working sheath/closure sheath system. The FISH InstaClose was very recently introduced procedure ending exchange system that delivers greatly simplified use, and shorter clinician learning curve. Both systems have multiple unique features and benefits that highly differentiate them from the competition. Morris has sold over 30,000 systems in the US so far, and recently received CE Mark approval, so the technology is very well proven.

Board Member

Glens Falls Hospital

Feb 2013 - Feb 2015 (2 years 1 month)

Glens Falls Hospital provides comprehensive health care services to Warren, Washington, northern Saratoga, Essex, Hamilton, and northern Rensselaer counties. Our 27 regional facilities include health centers in Cambridge, Corinth, Granville, Greenwich, Hoosick Falls, Salem, Whitehall, and Wilton.

Member of the Strategic Planning Committee, Patient Safety and Quality Committee

President & CEO

Delcath Systems Inc

Jul 2009 - Sep 2013 (4 years 3 months)

Delcath Systems and its proprietary targeted drug delivery system are at the forefront of the regional treatment of cancer. The Company's technology, known as ChemoSaturation (CS) for Percutaneous Hepatic Perfusion (PHP), allows physicians to deliver significantly higher doses of anti-cancer drugs to the site of disease without exposing the patient's entire body to those same potent levels of drug. Initial clinical results from studies treating cancer in the liver confirm that delivering more drug to the tumor site, and less to the other regions of the body, enhances tumor shrinkage with improved quality of life over systemic cancer therapies. PHP is approved and is pursuing reimbursement in the EU and is currently undergoing testing in Pha

Member, Board of Directors

Antares Pharma Inc

Jan 2009 - Jan 2016 (7 years 1 month)

Member Audit and Governance Committees
Antares Pharma, Inc. (NASDAQ: ATRS) is committed to developing and commercializing novel combination (drug and device) products utilizing the company’s unique, advanced drug delivery systems. ATRS products are patient focused: they typically improve safety and efficacy, reduce side effects and enable delivery at a lower dose. Antares advanced drug delivery systems are also well positioned for “life cycle extension” options.

C

Chairman of the Board of Directors

Cappella Cardiovascular Innovations Inc

Jan 2009 - Aug 2013 (4 years 8 months)

Chairman of the Board (only independent member)

Early commercial stage (EU), venture capital backed company with a unique solution to treating coronary artery side branch disease.

S

Member of the Board of Directors

Sentinelle Medical

Jan 2008 - Jan 2010 (2 years 1 month)

Member, Audit and Compensation Committees.
Sentinelle Medical Inc., established in 2004, is a private company based in Toronto, Canada that provides a suite of very high performance MR coils, and software solutions for GE, Toshiba and Siemens, providing health care providers with a fully integrated breast imaging and treatment planning system that result in the highest quality of patient care. Company achieved profitability and positive cash flow in Q4 2008. Very successful exit for investors upon sale of company to Hologic.

A

Member of the Board of Directors

American College of Phlebology Foundation

Jan 2006 - Jan 2009 (3 years 1 month)

Founding member of charitable scientific research and education foundation established in collaboration with its parent medical specialty society, American College of Phlebology, for the purpose of advancing the treatment of venous disease through research and education.

Assisted in the creation of the society’s first Strategic Plan.

Numerous committee memberships

S

Board Member

Society of Interventional Radiology Foundation

Jan 2002 - Jan 2008 (6 years 1 month)

SIRF is a charitable scientific research and education foundation established in collaboration with its parent medical specialty society, Society of Interventional Radiology, for the purpose of advancing interventional radiology through research and education.

Sole Industry member of the Board; numerous committee positions held throughout tenure.

Co-founder, President & CEO

AngioDynamics

Feb 1988 - Mar 2009 (21 years 2 months)

Co-founded a very successful medical device company that designs, develops, manufactures and markets image guided, minimally invasive devices for the targeted treatment of cancer and vascular disease. Company went from green field start up to leadership market share with premium positioning in core products against much larger, heavily entrenched competition.

About

Detail

Timeline

Résumé

Eamonn Hobbs

About

Detail

Behavioral traits